Two Sigma Advisers’s Eterna Therapeutics ERNA Stock Holding History

Two Sigma Advisers’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3	Closed	-$94K	–	2779
2021 Q4	$94K	Buy	+3	New	+$163K	﹤0.01%	2415

Other funds holding ERNA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CPWM

Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return

Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's ERNA Position: Q1 2022 in Review

Two Sigma Advisers sold out of Eterna Therapeutics (ERNA) in Q1 2022, closing a stake of 3 shares — an estimated $94K sold.

Two Sigma Advisers first reported a position in ERNA in Q4 2021 and held it in 1 quarter. The position peaked at $94K in Q4 2021. 49 funds tracked by Wall St. Rank hold ERNA as of Q1 2022.

Two Sigma Advisers reported no remaining Eterna Therapeutics position as of Q1 2022 after selling out during the quarter.
Two Sigma Advisers sold 3 Eterna Therapeutics shares in Q1 2022, an estimated $94K.
Two Sigma Advisers first reported a position in Eterna Therapeutics in Q4 2021 and held it in 1 quarter.
Two Sigma Advisers's Eterna Therapeutics position peaked at $94K in Q4 2021.
49 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2022.

Based on Two Sigma Advisers's 13F filing for Q1 2022, filed 16 May 2022.